- Home
- GROV vs ATYR Comparison
GROV vs ATYR Comparison
Compare GROV & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | ATYR |
|---|---|---|
| Founded | 2016 | 2005 |
| Country | United States | United States |
| Employees | 295 | 58 |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 50.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GROV | ATYR |
|---|---|---|
| Price | $1.23 | $0.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | $1.60 | ★ $3.67 |
| AVG Volume (30 Days) | 58.4K | ★ 3.3M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.40 |
| 52 Week High | $1.60 | $7.29 |
Technical Indicators
Market Signals| Indicator | GROV | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 37.89 |
| Support Level | $1.19 | $0.40 |
| Resistance Level | $1.58 | $0.86 |
| Average True Range (ATR) | 0.07 | 0.10 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 68.00 | 15.80 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).